Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

SARS-CoV-2 infection among patients with haematological disorders: Severity and one-month outcome in 66 Danish patients in a nationwide cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin Lymphoma and in Hodgkin Lymphoma survivors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review

    Research output: Contribution to journalReviewResearchpeer-review

  1. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. COVID-19 versus influenza A/B supeRInfectionS in the IntenSive care unit (CRISIS): Protocol for a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Andreas Glenthøj
  • Lasse H Jakobsen
  • Henrik Sengeløv
  • Syed A Ahmad
  • Kristian Qvist
  • Annika Rewes
  • Christian B Poulsen
  • Ulrik M Overgaard
  • Ingolf Mølle
  • Marianne T Severinsen
  • Casper N Strandholdt
  • Jack Maibom
  • Annette R Kodahl
  • Jesper Ryg
  • Pernille Ravn
  • Isik S Johansen
  • Søren N Helsø
  • Søren Jensen-Fangel
  • Jacek Kisielewicz
  • Lothar Wiese
  • Marie Helleberg
  • Ole Kirk
  • Michael R Clausen
  • Henrik Frederiksen
View graph of relations

OBJECTIVES: Patients with haematological disorders may be particularly vulnerable to respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, this is unknown.

METHODS: We conducted a prospective, nationwide study including 66 patients in follow-up at Danish haematology departments with a malignant or non-malignant haematological disorder and with verified SARS-CoV-2 infection. Outcomes were intensive care unit (ICU) admission and one-month survival rate.

RESULTS: Mean age was 66.7 years, 60.6% were males, 90.9% had comorbidity, and 13.6% had a BMI ≥ 30. The most frequent diagnoses were chronic lymphocytic leukaemia/lymphoma (47.0%), multiple myeloma (16.7%) and acute leukaemia/myelodysplastic syndrome (AL/MDS) (12.1%). Treatment for the haematological disease was ongoing in 59.1% of cases. Neutropenia was present in 6.5%, lymphopenia in 46.6% and hypogammaglobulinaemia in 26.3%. The SARS-CoV-2 infection was mild in 50.0%, severe in 36.4% and critical in 13.6%. After one month, 21.2% had been admitted to ICU, and 24.2% died. Mortality was highest in older patients, patients with severe/critical SARS-CoV-2 infection, high comorbidity score or high performance status score, purine analogue treatment and with AL/MDS. Although older patients and patients with comorbidities had the highest mortality rates, mortality was considerable among all haematological patients.

CONCLUSION: Haematological patients with SARS-CoV-2 infection has a severe clinical course.

Original languageEnglish
JournalEuropean Journal of Haematology
Volume106
Issue number1
Pages (from-to)72-81
Number of pages10
ISSN0902-4441
DOIs
Publication statusPublished - Jan 2021

    Research areas

  • Adult, Aged, Aged, 80 and over, COVID-19/mortality, Denmark/epidemiology, Female, Hematologic Neoplasms/mortality, Humans, Male, Middle Aged, Prospective Studies, SARS-CoV-2, Severity of Illness Index, immunology and infectious diseases

ID: 62072745